-55.9%
ADBE vs GSK
+47.2%
-103.1%
-69.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.4% | -1.0% | -1.3% | -2.3% |
| 7D | -12.9% | -5.4% | -7.5% | -12.5% |
| 30D | -5.6% | -4.6% | -1.0% | -5.2% |
| 3M | +6.6% | -5.1% | +11.7% | +7.2% |
| 6M | -9.6% | -11.4% | +1.9% | -8.7% |
| YTD | -28.9% | +0.7% | -29.6% | -29.3% |
| 1Y | -28.9% | +23.0% | -52.0% | -31.1% |
| All | -55.9% | +47.2% | -103.1% | -58.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling